CBLIF

Across TCGA pan-cancer cohorts, CBLIF mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CBLIF data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CBLIF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CBLIF expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

LSCC, GBM, and PDAC are the cancer types where CBLIF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.295	0.855	.006	15	view →
GBM	OS	Quartile	All	0.567	0.298	.023	10	view →
PDAC	OS	Median	All	0.727	0.933	.022	6	view →
LUAD	OS	Median	II,III,IV	1.000	0.580	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CBLIF–LSCC (DFS)

Open the LSCC breakdown →